Elevated CCL22 expression is associated with increased Treg recruitment into primary DCIS and IDC lesions, suggesting that Tregs may contribute to early breast cancer immunosuppression (Ohara et al., 2009). The gene discussed is CCL22; the disease is breast carcinoma.